Jun 24 |
Why Is Nano-Cap Revelation Biosciences Stock Skyrocketing On Monday?
|
Jun 24 |
Revelation Biosciences Announces Phase 1 Clinical Study of Gemini Met the Primary Safety Endpoint and Showed Statistically Significant Biomarker Activity
|
Jun 13 |
Revelation Biosciences Has Completed Dosing of its First in Human Phase 1 Clinical Study of Gemini
|
May 13 |
REVB: In Great Position For Testing
|
May 10 |
Revelation Biosciences GAAP EPS of -$2.46
|
May 10 |
Revelation Biosciences, Inc. Announces Financial Results for the Three Months Ended March 31, 2024
|
Mar 25 |
REVB Begins Trials with Good Cash on Hand
|
Mar 22 |
Revelation Biosciences GAAP EPS of -$8.33
|
Mar 22 |
Revelation Biosciences, Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2023
|
Mar 13 |
Revelation Biosciences Inc. Gives Oral Presentation at Advances in Critical Care Nephrology (AKI & CRRT 2024)
|